Sara S McCoy,Vivek Nagaraja,Scott Paviol,Johann E Gudjonsson, J Michelle Kahlenberg
Systemic Anti-malarial Drugs (SADs) are commonly used to treat autoimmune diseases and are generally considered a benign medication. SAD-induced psoriasis has been reported in the literature, but evidence is conflicting regarding the strength of the association of SAD and psoriasis exacerbations. We present a case of hydroxychloroquine-induced psoriasis exacerbation. The possible pathogenic mechanisms driving SAD-induced psoriasis are discussed and the relevant literature is reviewed.
